Aspire Pharma Ltd is pleased to announce a major new investment by an affiliate of H.I.G. Capital LLC., a global alternative investment firm with $45 billion of equity capital under management. The investment was announced September 24th, 2021 and will see H.I.G become the majority shareholder in Aspire Pharma Ltd, a leading UK provider of specialty pharmaceuticals. New members from H.I.G. will join the existing board of Aspire, which will remain in place, with Graham Fraser-Pye assuming the role of Chairman.
Through this investment, H.I.G will support future initiatives to continue Aspire’s impressive track record of organic growth, utilizing H.I.G’s extensive resources and capabilities in addition to Aspire’s robust product pipeline and capabilities in R&D, business development, and sales and marketing. Financial terms of the transaction have not been disclosed.
“H.I.G, with its significant financial and geographic reach, will help us maintain our impressive growth trajectory and take Aspire into another exciting phase for its people and its customers” remarked Graham Fraser-Pye. “We remain committed to the development and supply of innovative products and medicines that offer value to our customers and make a difference to the lives of patients”.